Axisresearch
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Countries
Chemoinformatics Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 112 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 112 pages
- Published: 07-06-2019
Market Overview
The propelling factors for the growth of the global chemoinformatics market include the innovations and advancements in the drug development process and increased demand of personalized medicine. The ever increasing growth of the drug development market is likely to boost the demand for chemoinformatics, owing to its numerous applications in drug designing at various stages. Right from target identification to its development as a potential drug candidate, chemoinformatics tools play a crucial part.
There has also been growing awareness related to personalized medicine, which has been driving the demand for effective medication, coupled with the unsustainable burden of chronic diseases. This serves as a compelling factor for new drug development, which promotes a positive impact on the growth of the global chemoinformatics market. These techniques find a vast array of applications in the various stages of drug designing. Furthermore, with the growing R&D intensity, the segment is further reinforced, owing to technological innovation inputs.
Scope of the Report
As per the scope of the report, chemoinformatics involves the application of computers to develop chemical data. With the help of chemoinformatics, study of chemical structures, and storage and analysis of the chemical data can be done easily. For the biological and pharmaceutical research organizations, visualization and analysis of data is necessary, and chemoinformatics helps in the management of such data. It is the use of computer and informational techniques applied to a range of problems in the field of chemistry.
Key Market Trends
Chemical Analysis Segment by Application is Expected to Grow Fastest During the Forecast Period
The chemical analysis segment accounted for the majority of the revenue share. The major factors that are contributing to the segment’s growth include the increasing investments in R&D and the relatively low success rate of the potential leads as drug molecules. The factors in conjunction with each other are expected to boost the usage of these platforms.
North America Holds the Largest Share and is Expected to Follow the Same Trend Over the Forecast Period
North America is likely to contribute to the largest share in the chemoinformatics market, owing to factors, such as enhanced healthcare of infrastructure, funds in initiatives of R&D, and technological enlargements in the United States and Canada. There has also been an increasing patient awareness about healthcare services and growing demand for personalized medicine that are likely to boost the market growth.
Competitive Landscape
The global chemoinformatics market has gained significant momentum in research institutions, pharmaceutical companies, biotechnology industry, research laboratories, and academic institutions. Therefore it is expected that over the course of time, there may be an influx of well-established players in the chemoinformatics market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Innovations and Advancements in the Drug Development Process
4.2.2 Increased Demand of Personalized Medicine
4.3 Market Restraints
4.3.1 Cost Associated with Chemoinformatics Software
4.3.2 Lack of Skilled Labors
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 By Application
5.1.1 Chemical Analysis
5.1.1.1 Chemical Databases
5.1.1.2 Chemo metrics
5.1.1.3 Molecular Modelling
5.1.1.4 Other Chemical Analyses
5.1.2 Drug Discovery and Validation
5.1.2.1 High Throughput Screening
5.1.2.2 Lead Identification and Optimization
5.1.2.3 QSAR/QSPR
5.1.2.4 Other Drug Discovery and Validations
5.1.3 Virtual Screening
5.1.4 Other Applications
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East & Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East & Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6. Competitive Landscape
6.1 Company Profiles
6.1.1 Dassault Systemes
6.1.2 Agilent Technologies
6.1.3 Bio-rad Laboratories Inc.
6.1.4 BioSolveIT GmbH
6.1.5 Cerep Inc.
6.1.6 ChemAxon Inc.
6.1.7 Chemical Computing Group Inc.
6.1.8 Jubilant Biosys Inc.
6.1.9 Molecular Discovery Ltd
6.1.10 OpenEye Scientific Software
7. Market Opportunities and Future Trends
By Application
Chemical Analysis
Chemical Databases
Chemo metrics
Molecular Modelling
Other Chemical Analyses
Drug Discovery and Validation
High Throughput Screening
Lead Identification and Optimization
QSAR/QSPR
Other Drug Discovery and Validations
Virtual Screening
Other Applications
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Clinical Trial Management Systems Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 118 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 118 pages
- Published: 07-06-2019
Market Overview
The clinical trial management systems market was valued at USD 665.90 million in 2017. Although the market has been in its nascent stage for the last five years, it has currently established itself as a mature market in the North American region. Asia-Pacific is still experiencing a high growth rate, when compared to other regions. This is mainly attributed to increasing clinical trials due to the high availability of inexpensive resources and increasing population pool in these regions. Moreover, the increased adoption of clinical trial management systems in the past few years has been a major factor that is contributing to the growth of this market.
Europe is expected to register a CAGR of 14.12%, as many Europeans regions are still in the process of adopting these systems. Many companies that have developed clinical trial management systems have found a way to integrate with the existing software providers, in order to provide an efficient workflow in clinical trial management.
The increasing innovative technological advancements to curb the increasing costs associated with clinical trials has resulted in the development of the clinical trials management system. Although these systems have not been completely adapted due to various factors, the increasing awareness and the need to cut down additional costs associated with clinical trials are expected to drive the market in the coming years. Increasing R&D and the rise in the number of clinical trials in the Asian region are expected to further contribute to the growth of the market studied, during the forecast period.
Scope of the Report
The clinical trial management systems market (henceforth, referred to as market studied’) is segmented on the basis of delivery mode, components, end user, and type of system. Based on delivery, the market is sub-segmented into web-based clinical trial management system, on-premise clinical trial management system, and cloud-based clinical trial management system. By component, the market is sub-segmented into software, hardware, and services. By end user, the market is sub-segmented into pharmaceuticals, contract research organizations, and other end users. Based on the type, the market is sub-segmented into site-based clinical trial management system and licensed enterprise-based clinical trial management system.
Key Market Trends
Cloud-based Clinical Trial Management Systems sub-segment is Expected to Exhibit Fastest Growth Rate Over the Forecast Period
Most big pharma and biotech companies are now increasingly adopting the cloud-based CTMS (clinical trial management systems). This increased adoption of cloud-based CTMS is because companies do not require to bear huge costs associated with the purchase of servers, and installation and validation of applications, and their maintenance. The new and advanced cloud-based CTMS facilitate the collaboration among the different groups at various sites to coordinate the successful completion of a trial.
BSI (Business Systems Integration AG) provides CTMS solution as a cloud or on-premise solution. Its functionality enhances the clinical trial operations from initial planning, implementation, reporting, patient monitoring, and entire documentation. Though data security is a typical challenge for cloud CTMS solution, most third-party providers have most advanced datacenters that require the users accessing the CTMS from outside company’s firewall to go through the authentication process. All the above factors are expected to contribute to sub-segment’s growth over the forecast period.
North America Captured the Largest Market Share and is Expected to Retain its Dominance
North America dominated the overall clinical trial management systems market, with the United States emerging as the major contributor to the market. Factors, such as increasing R&D investments and rise in the demand for drug development, are aiding the growth of the market studied in the country. R&D budgets of the pharmaceutical companies have also increased in the last few years, owing to the increasing focus on regulating markets, complex molecules, and therapy segments. In the United States, pharmaceutical companies spend more money, time, and energy on R&D than others.
According to ClinicalTrials.gov, in 2017, 262,433 clinical trials were carried out worldwide, which increased to 285,679 trials in 2018. Whereas, in the United States, 115,123 studies were carried out. Thus, the rise in clinical trials in the region is expected to increase the demand for clinical trial management systems, which, in turn, is expected to aid the growth of the market studied in the United States, over the forecast period.
Competitive Landscape
The presence of major market players, such as Bio-Optronics Inc., MedNet Solutions Inc., Oracle, Parexel International Corporation, and IBM, is, in turn, increasing the overall competitive rivalry of the market. Large organizations rely heavily on advertising expenses and branding strategies, collaborations, initiatives or programs at national levels, which promote their product, and thus, get recognized earlier than other brands in the market. With the high prevalence rate of diseases, the intensity of competitive rivalry in the market is increasing over time.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidences of Chronic Diseases and Lifestyle-related Disorders
4.2.2 Rise in Outsourcing of Clinical Trials and Implementation by Contract Research Organizations
4.2.3 Synchronization of Hospital Information System (HIS) with CTMS
4.3 Market Restraints
4.3.1 Data Security Issues
4.3.2 High Cost Associated with CTMS
4.3.3 Lack of Qualified and Skilled Labor to Handle CTMS
4.4 Industry Attractiveness- Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 By Delivery Mode
5.1.1 Web-based Clinical Trial Management System
5.1.2 On-premise Clinical Trial Management System
5.1.3 Cloud-based Clinical Trial Management System
5.2 By Component
5.2.1 Software
5.2.2 Hardware
5.2.3 Services
5.3 By End User
5.3.1 Pharmaceuticals
5.3.2 Clinical Research Organization
5.3.3 Other End Users
5.4 By Type of System
5.4.1 Site-based Clinical Trial Management System
5.4.2 Licensed Enterprise-based Clinical Trial Management System
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 United Kingdom
5.5.2.2 Germany
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East & Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6. Competitive Landscape
6.1 Company Profiles
6.1.1 Bioclinica
6.1.2 Bio-Optronics Inc.
6.1.3 DATATRAK International Inc.
6.1.4 ERT Clinical
6.1.5 IBM
6.1.6 Medidata Solutions Inc.
6.1.7 MedNet Solutions Inc.
6.1.8 Oracle
6.1.9 Parexel International Corporation
6.1.10 ArisGlobal
7. Market Opportunities and Future Trends
By Delivery Mode
Web-based Clinical Trial Management System
On-premise Clinical Trial Management System
Cloud-based Clinical Trial Management System
By Component
Software
Hardware
Services
By End User
Pharmaceuticals
Clinical Research Organization
Other End Users
By Type of System
Site-based Clinical Trial Management System
Licensed Enterprise-based Clinical Trial Management System
Geography
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
CLINICAL TRIALS MARKET- GROWTH, TRENDS, AND FORECAST (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 117 pages | Published: 24-06-2019 |
- Healthcare
- Mordor Intelligence
- 117 pages
- Published: 24-06-2019
Market Overview
The major factors found propelling the growth of the market include the high demand for clinical trials in emerging markets, high R&D spending of the pharmaceutical industry, an increasing prevalence of diseases, and the focus on rare diseases and multiple orphan drugs in the pipeline.
The market is growing at a robust pace, owing to the advancements in healthcare and growing patented new chemical entities (NCE) indicated for various health conditions.
It has also been found that there are a large number of unmet clinical needs in emerging countries, due to the prevalence of infectious and tropical diseases in the region. Owing to these, a large number of the population participate in clinical trials to access high-quality healthcare free of cost. India and China have the highest prevalence rates for metabolic disorders, due to the increasing population, combined with the prevalence of insulin resistance, hyperlipidemia, and obesity.
In addition, government initiatives have also motivated the small, medium, and large players to enter into orphan drug development. Thus, there are multiple drugs in the pipeline. As a result, Novartis, GlaxoSmithKline, and Pfizer (among others) have entered this field. It has also been found that the clinical trials market has taken bigger strides in the developing countries of Asia-Pacific and the Middle East and there is still very less development in the market.
Scope of the Report
As per the scope of the report, clinical trials are experiments that are conducted under clinical research and follow a regulated protocol. These experiments are primarily performed to obtain data regarding the safety and efficacy of newly developed drugs. Clinical trial data is mandatory for drug approval, as well as for it to be introduced in the market. These trials are performed under three phases (I, II, and III), which depends upon various factors. This process is not only expensive, but also time consuming, and requires expertise at all stages.
Key Market Trends
Phase III is the Largest Segment Under Phases that is Expected to Grow During the Forecast Period
The market is expected to be dominated by Phase III, with Phase I expected to witness the fastest growth. Phase III is one of the most critical phases assessing the effectiveness of the new intervention, as well as its value in clinical practice. The Phase I trial in the market studied is also expected to grow at a steady rate, due to the increasing number of investigative new drug (IND) applications filed. The government initiatives in emerging economies for the promotion of drug discovery and continuous technological innovations are expected to propel the market growth.
North America has been Reported with the Largest Growth that is Expected to Follow the Same Trend over the Forecast Period
North America dominated the overall market, owing to the presence of big outsourcing firms and increasing R&D in the region. However, increasing R&D investments and an increasing demand for drug development are the major factors responsible for the market emergence in the United States.
Competitive Landscape
The major pharmaceutical companies are found making enormous investments in R&D, especially in the emerging nations, in order to gain opportunities for market growth in the major regions. The strategic partnerships among pharmaceutical companies and the CROs are expected to have a significant impact on the market’s growth.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Demand for Clinical Trials in the Emerging Markets
4.2.2 High R&D Expenditure of the Pharmaceutical Industry
4.2.3 Rising Prevalence of Diseases
4.2.4 Focus on Rare Diseases and Multiple Orphan Drugs in the Pipeline
4.3 Market Restraints
4.3.1 Lack of Skilled Workforce Clinical Research
4.3.2 Lower Healthcare Reimbursement in the Developing Countries
4.3.3 Stringent Regulations for Patient Enrollment
4.4 Porter’ s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Phase
5.1.1 Phase I
5.1.2 Phase II
5.1.3 Phase III
5.1.4 Phase IV
5.2 By Design
5.2.1 Treatment Studies
5.2.1.1 Randomized Control Trial
5.2.1.1.1 Double Blind Trial Randomized Trial
5.2.1.1.2 Single Blind Trial Randomized Trial
5.2.1.1.3 Non-blind Randomized Trial
5.2.1.2 Adaptive Clinical Trial
5.2.1.3 Non-randomized Control Trial
5.2.2 Observational Studies
5.2.2.1 Cohort Study
5.2.2.2 Case Control Study
5.2.2.3 Cross Sectional Study
5.2.2.4 Ecological Study
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Clinipace
6.1.2 Laboratory Corporation of America
6.1.3 Eli Lilly and Company
6.1.4 ICON PLC
6.1.5 Novo Nordisk AS
6.1.6 PAREXEL International Corporation
6.1.7 Pfizer Inc.
6.1.8 Pharmaceutical Product Development LLC
6.1.9 IQVIA
6.1.10 F. Hoffmann-La Roche Ltd
6.1.11 Sanofi
6.1.12 Wuxi AppTec
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Phase
Phase I
Phase II
Phase III
Phase IV
By Design
Treatment Studies
Randomized Control Trial
Double Blind Trial Randomized Trial
Single Blind Trial Randomized Trial
Non-blind Randomized Trial
Adaptive Clinical Trial
Non-randomized Control Trial
Observational Studies
Cohort Study
Case Control Study
Cross Sectional Study
Ecological Study
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Companion Diagnostics Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 118 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 118 pages
- Published: 07-06-2019
Market Overview
The growth of the global companion diagnostics market can be attributed to the rising focus on personalized medicine and co-development of drug and diagnostic technologies. In addition, rising cases of adverse drug reactions related to drugs, due to the lack of efficacy, drive the need for companion diagnostics. One of the major factors driving the growth of the companion diagnostics market is the increasing demand for personalized medicines and awareness about the same among the population. With companies increasing their collaborations for better biomarkers and diagnostics, in order to focus on cost regulations, there has been significant number of opportunities for its applications in indications, like cancer, cardiovascular and neurological disorders, etc.
Scope of the Report
Companion diagnostic tests provide information that is essential for the safe and effective use of a corresponding drug or biological product. As per the scope of the report, the market studied has been segmented by technology, indications, and geography. By technology, the market studied has been further segmented into immunohistochemistry, polymerase chain reaction, in-situ hybridization, real time-polymerase chain reaction, gene sequencing, and other technologies.
Key Market Trends
In-situ Hybridization (ISH) Segment is Expected to Exhibit Fastest Growth Rate Over the Forecast Period
In-situ hybridization (ISH), especially fluorescence in-situ hybridization (FISH), is a reliable, reproducible, sensitive, and accurate procedure, which is less affected by tissue fixation and analytical variables, in comparison to immunochemistry and other techniques. It offers the benefit of simultaneous evaluation of morphology and gene amplification. FISH has been the method of choice for use in companion diagnostics for several cancer therapies, such as trastuzumab, lapatinib, and criotinib, which have been already approved by FDA and other therapies, like everolimus, ridaforolimus, bicatulamide, TBD, and other drugs, that are yet to obtain regulatory approval.
The global market for in-situ hybridization in CDx is growing because of technological advancements, like the recent development of bright-field in-situ hybridization techniques, chromogenic in-situ hybridization (CISH), and the automated silver-enhanced in-situ hybridization (SISH) for the determination of gene status. Thus, considering the aforementioned factors, the ISH segment is expected to exhibit growth over the forecast period.
North America Captured the Largest Market Share and is Expected to Retain its Dominance
North America dominated the overall companion diagnostics market, with the United States emerging as the major contributor to the market. The use of companion diagnostics is taking up a central role as an important treatment decision tool for a number of oncology drugs, which is also reflected in the way the FDA classifies these assays in relation to risk. In the United States, companion diagnostic assays are classified as IVD class III products, which represents a high-risk category, and consequently, the highest level of regulatory control. Hence, owing to high healthcare technology adoption rates and increasing demand for personalized medicine, the market for companion diagnostics in the United States is expected to register a substantial growth rate during the forecast period.
Competitive Landscape
The presence of major market players, such as Abbott, Agilent Technologies, F. Hoffmann-La Roche Ltd, Biomerieux SA, and Qiagen NV, is, in turn, increasing the overall competitive rivalry of the market. But the issues associated with the high development cost and poor reimbursement are affecting the market negatively. However, the rising focus of companies toward personalized medicine, co-development activities, and increased cases of adverse drug reactions is expected to boost the competitive rivalry in the market studied.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Companies Promoting Personalized Medicine and Targeted Therapy as a New Treatment Option
4.2.2 Increasing Cases of Adverse Drug Reactions
4.2.3 Co-development of Drug and Diagnostic Technology
4.3 Market Restraints
4.3.1 High Cost of Drug Development and Associated Clinical Trials
4.3.2 Reimbursement Issues among Many Countries
4.4 Industry Attractiveness- Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 By Technology
5.1.1 Immunohistochemistry (IHC)
5.1.2 Polymerase Chain Reaction (PCR)
5.1.3 In-situ Hybridization (ISH)
5.1.4 Real-time PCR (RT-PCR)
5.1.5 Gene Sequencing
5.1.6 Other Technologies
5.2 By Indication
5.2.1 Lung Cancer
5.2.2 Breast Cancer
5.2.3 Colorectal Cancer
5.2.4 Leukemia
5.2.5 Melanoma
5.2.6 Other Indications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 United Kingdom
5.3.2.2 Germany
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. Competitive Landscape
6.1 Company Profiles
6.1.1 Abbott
6.1.2 Agilent Technologies Inc.
6.1.3 F. Hoffmann-La Roche Ltd
6.1.4 Biomerieux SA
6.1.5 Qiagen NV
6.1.6 Siemens Healthcare
6.1.7 Thermo Fisher Scientific Inc.
6.1.8 Danaher Corporation (Beckman Coulter Inc.)
7. Market Opportunities and Future Trends
By Technology
- Immunohistochemistry (IHC)
Polymerase Chain Reaction (PCR)
In-situ Hybridization (ISH)
Real-time PCR (RT-PCR)
Gene Sequencing
Other Technologies
By Indication
Lung Cancer
Breast Cancer
Colorectal Cancer
Leukemia
Melanoma
Other Indications
Geography
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Spain
Rest of Europe - Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Computational Biology Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 115 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 115 pages
- Published: 07-06-2019
Market Overview
The global computational biology market was valued at USD 2,327.06 million in 2018, and is estimated to be valued at USD 6,790.06 million in 2024, witnessing a CAGR of 19.54%. Factors that are responsible for the growth of the market include increase in bioinformatics research, increasing number of clinical studies in pharmacogenomics and pharmacokinetics, and growth of drug designing and disease modeling.
Bioinformatics is recognized as part of the essential knowledge base of numerous career paths in biomedical research and healthcare. The field of bioinformatics and computational biology has gone through a number of transformations over the past 15 years, establishing itself as a key component of new biology. The use of bioinformatics tools in life sciences has become necessary to analyze experimental data. The huge amounts of data pose a challenge for the biological community, as most biologists are not familiar with informatics and statistical interpretation. An interdisciplinary collaboration was started with an aim to address the need for biologists to understand biological data.
Recent improvements in bioinformatics include capacity-building through activities, such as research funding and training opportunities. Increased funding in bioinformatics is helping in creating more advancements in the field of computational biology.
Scope of the Report
Computational biology uses biological data for developing algorithms to understand biological systems and relationships.
Key Market Trends
Commercial Sub-segment is Expected to hold its Highest Market Share in the End User Segment
In the end user segment of the market, the commercial sub-segment is believed to have the largest market size and is expected to witness a CAGR of 19.87% during the forecast period.
Computational biology has a wide range of applications in the fields of genomics, proteomics, pharmacogenomics, and drug discovery. For drug discovery and clinical trials, many companies approach third-party services, who have to maintain computational biology setups for carrying out various drug discovery processes. Many third-party services and small laboratories that maintain computational biology setups are expected to gain huge profits, as they successfully reduce the overall time needed for drug discovery and various other scientific experiments.
The software and databases are relatively costlier, and the cost of drug discovery processes vary across countries, which makes many industries opt for outsourcing, thereby, leading to an increased demand for small laboratories and other commercial companies. Hence, with the increase in bioinformatics research, the increasing number of clinical studies in pharmacogenomics and pharmacokinetics, and the growth of drug designing, disease modeling, and personalized medicine, the demand for computational biology for commercial purposes is expected to increase, thereby, driving the market during the forecast period.
North America Dominates the Market and is Expected to do the Same in the Forecast Period
North America currently dominates the market for computational biology and is expected to continue its stronghold for a few more years. The United States is the leading nation in the field of synthetic biology, which is an emerging discipline involving the creation, control, and reprogramming of biological systems. Since 2005, the US government has channeled more than USD 1 billion for the development of computational biology and synthetic biology. The annual average expenditure for the development of computational biology, by the US government, has been estimated to be USD 140 million.
The overall market for computational biology in the United States is scheduled to grow manifold, over the forecast period, primarily due to high expenditure in drug development endeavors (highest in the world).
Competitive Landscape
The computational biology market is expected to become highly competitive in the near future, as it consists of several major players. With increasing technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new products with fewer prices. Companies, like Dassault Systems, Chemical Computing Group Inc., Leadscope Inc., Compugen Ltd, and Rhenovia Pharma SAS, hold substantial shares in the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Bioinformatics Research
4.2.2 Increasing Number of Clinical Studies in Pharmacogenomics and Pharmacokinetics
4.2.3 Growth of Drug Designing and Disease Modeling
4.3 Market Restraints
4.3.1 Lack of Trained Professionals
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Application
5.1.1 Cellular and Biological Simulation
5.1.1.1 Computational Genomics
5.1.1.2 Computational Proteomics
5.1.1.3 Pharmacogenomics
5.1.1.4 Other Cellular and Biological Simulations (Transcriptomics/Metabolomics)
5.1.2 Drug Discovery and Disease Modelling
5.1.2.1 Target Identification
5.1.2.2 Target Validation
5.1.2.3 Lead Discovery
5.1.2.4 Lead Optimization
5.1.3 Preclinical Drug Development
5.1.3.1 Pharmacokinetics
5.1.3.2 Pharmacodynamics
5.1.4 Clinical Trials
5.1.4.1 Phase I
5.1.4.2 Phase II
5.1.4.3 Phase III
5.1.5 Human Body Simulation Software
5.2 By Tool
5.2.1 Databases
5.2.2 Infrastructure (Hardware)
5.2.3 Analysis Software and Services
5.3 By Service
5.3.1 In-house
5.3.2 Contract
5.4 By End User
5.4.1 Academics
5.4.2 Industry
5.4.3 Commercial
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East & Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Dassault Systèmes SE
6.1.2 Certara
6.1.3 Chemical Computing Group ULC
6.1.4 Compugen Ltd
6.1.5 Rosa & Co. LLC
6.1.6 Genedata AG
6.1.7 Insilico Biotechnology AG
6.1.8 Leadscope Inc.
6.1.9 Nimbus Discovery LLC
6.1.10 Strand Life Sciences
6.1.11 Schrodinger
6.1.12 Simulation Plus Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Application
Cellular and Biological Simulation
Computational Genomics
Computational Proteomics
Pharmacogenomics
Other Cellular and Biological Simulations (Transcriptomics/Metabolomics)
Drug Discovery and Disease Modelling
Target Identification
Target Validation
Lead Discovery
Lead Optimization
Preclinical Drug Development
Pharmacokinetics
Pharmacodynamics
Clinical Trials
Phase I
Phase II
Phase III
Human Body Simulation Software
By Tool
Databases
Infrastructure (Hardware)
Analysis Software and Services
By Service
In-house
Contract
By End User
Academics
Industry
Commercial
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Computed Tomography (CT) Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 110 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 110 pages
- Published: 07-06-2019
Market Overview
The major factors for the growth of the global computed tomography (CT) market include the rising geriatric population and increase in incidences of chronic diseases, increase in the shift of medical care toward image-guided interventions, and technological advancements.
The burden of chronic diseases is on the rise across the world, and medical imaging procedures play a crucial role in the accurate diagnosis of these diseases. Chronic diseases, such as heart disease, stroke, cancer, diabetes, obesity, and arthritis, are among the most common, expensive, and preventable of all health problems. According to the estimates of World Health Organization (WHO), non-communicable diseases (NCDs) account for 63% of all deaths (36 million out of 57 million global deaths) and 80% of the deaths occur in low- and middle-income countries. Cancer, cardiovascular diseases, diabetes, chronic kidney diseases, and respiratory diseases were the primary causes of death. The global cancer burden is expected to increase by 70% in the next two decades. Tobacco use, physical inactivity, alcohol consumption, and unhealthy diets create a risk of death from the aforementioned non-communicable disease. To prevent the impact of chronic diseases on individuals and society, research is being carried out for the early detection of such disorders. The access to technology and relative cost of CT procedures, as compared to other modalities, make it a preferred choice of imaging. CT scan is being increasingly used to diagnose these diseases, which is also increasing its demand.
Scope of the Report
As per the scope of the report, computed tomography (CT) is an imaging process that customizes special X-ray equipment to generate a sequence of exhaustive images, or scans, of areas inside the body. Also called computerized axial tomography (CAT) scanning, it is primarily used in cancer diagnosis. The market is segmented by type, application, end user, and geography.
Key Market Trends
Oncology Segment by Application is Expected to Account for Largest Market Share during the Forecast Period
Oncology deals with the diagnosis and treatment of tumors and cancers, while cancer is one the leading causes of morbidity and mortality. Among both sexes, lung, breast, and colorectal cancers are among the most common cancers in the world, with lung cancer alone contributing to more than 13% of the total cases diagnosed.
The global cancer burden is increasing, and thus, there is a rise in the usage of imaging modalities for the diagnosis of the diseases. According to the World Cancer Research Fund, in 2018, there were an estimated 18 million cancer cases around the world, out of which, 9.5 million cases were in men and 8.5 million in women. Lung and breast cancers were the most common, globally, and contributed to 12.3% of the total number of new cases that were diagnosed in 2018. Colorectal cancer was the third-most common cancer, with a prevalence of 1.8 million new cases in 2018, according to the World Cancer Research Fund. The increasing cancer burden is due to a number of factors, including population growth and aging, and the changing prevalence of certain causes of cancer is linked to social and economic development. Cancer is also associated with lifestyles. As CT scans are relatively less expensive, as compared to other imaging modalities, hence the segment is expected to witness a healthy CAGR over the forecast period.
North America Accounted for the Largest Share in the Global Market
North America is found to hold a significant share in the computed tomography (CT) market, and it is expected to show a similar trend over the forecast period, without substantial fluctuations. The market growth in the United States can be attributed to the rising geriatric population. As the population ages, more cancer and chronic diseases are likely to be identified. With the increasing image-guided radiotherapy (IGRT) for image guidance, the CT market is forecast to grow at a steady pace. Also, patients seek more precision in the ability to target and treat cancers, which is aiding the market growth in the United States. In the United States, hospitals are fronting increased patient flow per CT scanner. The utilization per CT scanner at services that are not affiliated with hospitals is decreasing; about 20% more in hospitals when compared to other services. Also, recent advancements have also increased the use of CT scans in various diseases. In November 2016, Toshiba (Canon Medical Systems Corporation) introduced its first system that improves image quality with significant noise reduction, while reducing radiation dosage.
Competitive Landscape
The global computed tomography (CT) market is a consolidated market, owing to the presence of a few major players in the market. The major market players, such as Canon Medical Systems Corporation, Koninklijke Philips NV, GE Healthcare, and Siemens Healthineers, hold a significant market share in the industry. Most of the market players are focusing on bringing technologically advanced products in the market to acquire the maximum market share.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Geriatric Population and Increase in Incidences of Chronic Diseases
4.2.2 Increase in Shift of Medical Care Toward Image-guided Interventions
4.2.3 Technological Advancements
4.3 Market Restraints
4.3.1 Lack of Adequate Reimbursement
4.3.2 Stringent Regulatory Framework
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Low Slice
5.1.2 Medium Slice
5.1.3 High Slice
5.2 By Application
5.2.1 Oncology
5.2.2 Neurology
5.2.3 Cardiovascular
5.2.4 Musculoskeletal
5.2.5 Other Applications
5.3 By End User
5.3.1 Hospitals
5.3.2 Clinics
5.3.3 Diagnostic Services
5.3.4 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Canon Medical Systems Corporation
6.1.2 Fujifilm Holdings Corporation
6.1.3 GE Healthcare
6.1.4 Hitachi Healthcare Systems
6.1.5 Koning Corporation
6.1.6 Koninklijke Philips NV
6.1.7 NeuroLogica Corporation
6.1.8 Neusoft Medical Systems Co. Ltd
6.1.9 Shenzhen Anke High-Tech Co.
6.1.10 Siemens Healthineers
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Type
Low Slice
Medium Slice
High Slice
By Application
Oncology
Neurology
Cardiovascular
Musculoskeletal
Other Applications
By End User
Hospitals
Clinics
Diagnostic Services
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America